SI-BONE (SI-BONE) Interest Expense : $-3.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SI-BONE's interest expense for the three months ended in Dec. 2023 was $ -0.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SI-BONE's Operating Income for the three months ended in Dec. 2023 was $ -12.5 Mil. SI-BONE's Interest Expense for the three months ended in Dec. 2023 was $ -0.9 Mil. SI-BONE did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SI-BONE Interest Expense Historical Data

The historical data trend for SI-BONE's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE Interest Expense Chart

SI-BONE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.95

-6.10

-5.37

-2.82

-3.46

SI-BONE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.88	-0.84	-0.85	-0.88	-0.89

SI-BONE Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.5 Mil.

SI-BONE (NAS:SIBN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SI-BONE's Interest Expense for the three months ended in Dec. 2023 was $-0.9 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-12.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $37.6 Mil.

SI-BONE's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

SI-BONE did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

SI-BONE (SI-BONE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050

Website

http://www.si-bone.com

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Executives

Anshul Maheshwari	officer: Chief Financial Officer	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero	officer: Chief Commercial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn	director, officer: Chairman, President & CEO	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis	officer: Chief Financial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky	officer: GC & Chief Compliance Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh	director	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp	10 percent owner	525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling	officer: CMO and VP, Medical Affairs	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby	officer: Chief Technology Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan	director	452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451